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The re-uptake of neurotransmitters inlo the nerve terminal terminates synaptic transmission at most central synapses and constitutes a key step 
in the modulation or synaptic efficacy. Recently, the cloning of several Na’-driven neurotransmitter transporters has resulted in the description 
ofa novel lamily of homologous membrane proteins, each with I2 Lrtansmcmbrane segments. These transporters constitute major targets or widely 
used drugs, and modulation of transporter gene xpression and/or activity may represent an important substrate forplasticity in the nervous ystem. 
Neurotransmittcr: Transporter; Nervous system 
1 o INTRODUCTION 
Plasma membranes are practically impermeable to 
polar molecules and build a tight barrier between the 
inner and outer milieu of the cell. Specialized transmem- 
brane proteins are therefore required to translocate ions 
and metabolites across the lipid bilayer. Channel pro- 
teins allow the passage of different ions and/or small 
molecules along their electrochemical gradients, 
whereas carrier proteins transport bound substrates, 
even against steep concentration gradients. The latter 
process requires metabolic energy and/or coupling for 
the co-transport of ions. In this review, we discuss a 
special type of carrier system, the Na+-driven euro- 
transmitter transporters, which recently emerged as a 
novel family of integral membrane proteins. 
During neurotransmission, eurotransmitters un- 
dergo the following ‘life cycle’ at ihe synapse: (i) exocy- 
totic release from plasma membrane attached synaptic 
vesicles into the nerve terminal; (ii) binding to their 
target receptors, thereby mediating signal transduction 
through the postsynaptic membrane; (iii) dissociation 
from the receptor followed by re-uptake into the presyn- 
aptic terminal or surrounding lial cells; and (iv) trans- 
port from the presynap:ic ytosol into synaptic vesicles. 
Transmitter uptake through the plasma membrane 
(iii) is driven by Na’, whereas transport into synaptic 
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vesicles (iv) is driven by a vesicular proton pump. In this 
cycle, efficient re-uptake of the transmitter from the 
synaptic left constitutes the crucial termination step of 
neurotransmission, asis amply documented for the neu- 
rotransmitters norepinephrine, dopamine, serotonin, L- 
glutamate, y-aminobutyric acid (GABA) and glycine. 
Another mechanism of inactivation is found for ace- 
tylcholine, which, after dissociation from the receptor, 
is hydrolyzed into choline and acetate. Choline then is 
recovered by Na*-dependent transport, as described 
above, and re-utilized for the de novo synthesis of ace- 
tylcholine in the nerve terminal. 
The regulation of transporter activity is thought to 
constitute an important mechanism for the control of 
neurotransmittcr action. Short-term changes of gluta- 
mate and choline transport in brain have been demon- 
strated to result from activation of the second messen- 
gers, Ca’+ and arachidonic acid, and/or membrane de- 
polarization [1,2], As arachidonic acid is released upon 
induction of long-term potentiation in the hippocampus 
[3], the modulation of transporter activity may have an 
important role in synaptic plasticity and learning proc- 
esses. Moreover, permanent changes in transporter 
gene expression may contribute to persistent modifca- 
lions of synaptic efficacy. 
Transmitter uptake systems are also of great medical 
interest, since these membrane proteins represent he 
target sites of many clinically important drugs and may 
be implicated in neurological and psychiatric disorders. 
For example, tricyclic antidepressants inhibit both 
norepinephrine and scrotonin transport, amphetamines 
block dopamine and norepinephrine uptake, and co- 
caine inhibits all these transport systems. Most of the 
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aforementioned compounds cause profound changes in 
behaviour, and have high abuse potential. Interestingly, 
the concentration of serotonin and its metabolites is 
lowered in the cerebrospinal f uid of alcohol abusers, 
and administration of specific serotonin uptake inhib- 
itors decreases ethanol intake [4]. Also, high-affinity 
choline uptake may be important for the selective vul- 
nerability of cholinergic neurons in Alzheimer’s disease 
[5]. The detailed functional and pharmacological naly- 
sis ofdifferent ransmitter uptake systems thus may help 
to elucidate pathogenic mechanisms and to develop 
novel, therapeutically useful compounds. 
2. ANALYSIS OF NEUROTRANSMITTER 
TRANSPORTER FUNCTION 
Several methodologies have been used to to analyse 
the functional and pharmacological characteristics of 
neurotransmitter t ansporters. Determination of the 
uptake of radioactive transmitters into synaptosomes, 
cultured cells, and plasma membrane fractions display- 
ing transmembrane ion gradients allowed evaluation of 
transport kinetics, and revealed a strict dependence on 
extracellular Na’. Often, Cl- ions are, in addirion, re- 
quired. This Cl- dependence discriminates the neuro- 
transmitter transporters from other Nat-driven trans- 
port proteins. In the case of the rat brain glutamate and 
glycine uptake systems, 2-3 Na* and 1 Cl- ions are 
co-transported per substrate molecule translocated 
[6,7]. Similar results were also obtained after reconstitu- 
tion of the solubilized transporters into liposomes. In 
fact, rapid reconstitution, followed by determination of 
tracer uptake, served as an assay for the purification of 
functional GABA transporter protein [S]. Since the 
transport process is electrogenic, electrophysiological 
methods may also be employed. Indeed, in a recent 
report the whole-cell patch-clamp method was used to 
monitor the kinetics of glutamate uptake [6,9]. More 
recently, heterologous expression in Xmopus oocytes 
and mammalian cells has been employed to analyse 
transporters encoded by brain RNA fractions or iso- 
lated cDNAs. In fact, all transporter cDNAs cloned to 
date (see below) have been verified using this approach 
[l l-211. As heterologous expression allows analysis of 
individual functional proteins, this technique will have 
an important place in future studies of neurotransmitter 
uptake. 
3. PROTEIN STRUCTURE 
Biochemical purification of glutamate, GABA and 
choline transporters resulted in the identification ofprc- 
teins of approximately 80 kDa [lo]. Microsequencing of
cyanogen bromide fragments of the purified rat GABA 
transporter (GATl) then allowed cDNA cloning of the 
Arst neurotransmitter t ansporter [I 13. Using expres- 
sion cloning strategies and amplification of related se- 
quences by the polymerase chain reaction (PCR), 
cDNAs encoding Na’-dependent transporters for 
norepinephrine [12j, serotonin [13-151, dopamine [16- 
191 and choline [20] have been isolated. Comparison of 
the deduced polypeptide sequences reveals that all these 
proteins hare significant amino acid identity (30-65%) 
and a common predicted transmembrane topology, 
each with 12 putative membrane spanning segments 
(Figs. 1 and 2). As a hydrophobic N-terminus display- 
ing characteristics of a signal peptide is lacking, the 
extended N- and C-termini are assigned to the cyto- 
plasm. In most transporters, these cytoplasmic tail re- 
gions contain consensus phosphorylation sites which 
may be important for the regulation of transporter ac- 
tivity. Mowever, reconstitution experiments with prote- 
olytically cleaved GATl indicate that neither the N- nor 
the C-terminal regions are essential for transport func- 
tion [22]. A long putative xtracellular domain contain- 
ing N-glycosylation sites is conserved between trans- 
membrane segments III and IV (Fig. 2). In the case of 
GATl, glycosylation at these sites appears to be re- 
quired for incorporation into the plasma membrane 
[23]. The structural design shown in Fig. 2 is highly 
conserved between all neurotransmitter transporters se- 
quonced to date. Interestingly, II-12 putative trans- 
membrane segments are also found in many, otherwise 
unrelated, Na’-driven symporter proteins including the 
hexose transporters [24]. This may be indicative of con- 
vergent evolution, resulting in a common transmem- 
brane architecture for diverse members of a super-fam- 
ily of Na’driven plasma membrane transport proteins. 
Some conserved sequence features of the neurotrans- 
mitter transporter proteins allow further deductions 
about the possible structure of these membrane pro- 
teins, First, the putative transmembrane segment I
shows a very high degree of conservation (Fig. I), but 
only a low content of hydrophobic residues. This scg- 
ment may thus participate in ion translocation and 
probably is centrally positioned in the asse,mbled trans- 
porter. Segment IX, in contrast, is not well conserved 
and may contribute to substrate binding. At. least two 
segments, VI and VII, display a highly amphipathic 
character and are thus potentially suited to line a trans- 
port path, Regions involved in Na’ translocation have 
not been identified, however, a glutamate residue is ab- 
solutely conserved in a central position of transmem- 
brane segment X. This side chain might constitute an 
intramembrane binding site for Na”; alternatively, it
may stabilize transporter conformation by pairing with 
other intramembrsne charged residues, e.g. a conserved 
arginine in segment 1. A sequence reminiscent of a de- 
generate leucine zipper motif overlaps transniembranr 
segment 11 and has been discusicd as a possible dimer- 
ization signal [25]. This raises the interesting possibility 
that, in common with the intestinal glucose transporter, 
which functions as a homotetramer [26], neurotransmit- 
ter transporters may be oligomeric proteins. 
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Fig. I. Alignnment orNa’-dependent transporwr proteins. Sequences arc taken I’rom the Lbllowing rc~ercnces: BGTI [27]; GATI [I I]: NETI 1131; 
DATI [l6-191; SERTI [l3-151; and CHOTI [20]. Amino acids identical inail transportersarc marked by asterisks, and isoLmctional residues shared 
by at Icust four proteins by a dot. Putative transmembranc regions arc indicated by bars. Gaps are introduced to optimize identical sequence 
positions. A dendrogram at the C-terminal end or the scqucnccs symbolizes the homology relationships between the individual transporters. 
4. HETERQGENEITY OF TRANSPORTERS 
Presently, transporters for four different neurotrans- 
mitters and for choline have been cloned. In addition, 
the isolation of a cDNA encoding a Na’-dependent 
betaine transporter (BGTl) has been reported [27]. Its 
high amino acid sequence homology (see Fig. 1) identi- 
fies this osmolyte carrier as a member of the Na’-driven 
neurotransmitter t ansporter family. However, corre- 
sponding transcripts are only found in kidney. lnterest- 
ingly, BGTl also transports GABA with an even higher 
afinity than betaine. Thus, fcr GABA traIlsport two 
different proteins have been identified at the molecular 
level; GATI, which is neurally expressed and BGTl, 
75 
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Fig, 2. Proposed lransmembranc topology or transporlcr proteins. 
Putative transmcmbranc scyments are shown as boxes; N- and C- 
tcrmini are localized in the cytoplasm. and putalivc glycosylation shcs 
(Y) are indicated on the sesond extracellular loop. E. glutamate rcsi- 
due in transmembrunc segment X; +++. conserved cluster of posi- 
tively charged residues prcceeding transmcmbranc seyment IX. 
which is renally expressed. However, a much higher 
diversity of’ GABA transporters is predicted from up- 
take studies. Ns+-driven transport of taurine, /3-alanine 
and GABA by a single transport system has been dcm- 
onstratcd in cultured glioma cells [28], and two pharma- 
cologically distinct high-affinity GABA transporters 
have been described in plasma membrane vesicles from 
rat brain [29]. One of these transporters is expressed 
only in neurons and recognized by a CiATl specific 
antiserum, whereas the other is localized in glial cells 
and is immunologically unrelated to GATI [30]. In ad- 
dition, low-affinity GABA uptake is observed in brain, 
and pharmacological evidence indicates that different 
glial GABA uptake systems may exist [3 1,32]. Similarly, 
heterogeneity of dopamins transporters has been pre- 
dicted, based on the observation that striatal membrane 
preparations reveal two different binding sites for 
[“HIcocaine, both of which are associated with the 
dopamine uptake system [33,343. Thus, considerable di- 
versity of neurotransmitter t ansporters may exist in 
brain and contribute to the functional heterogeneity of
synapses. However, such heterogeneity may originate 
not only from expression of multiple transporter genes, 
but may also result from post-translational modifica- 
tion and/or the state of oligomerization of these mem- 
brane proteins, Moreover, different binding sites and/or 
affinity states for the substrate may exist on a single 
transporter. A recent report indeed shows that expres- 
sion of a single dopamine transporter cDNA in COS 
cells generates two cocaine binding sites of different 
affinity [35]. In other words, functional diversity of neu- 
rotransmittcr transporters may originate by both tran- 
scriptional and post-transcriptional mechanisms. 
5. CONCLUSIONS 
Recent cDNA sequence data have established that 
neurotransmitler t ansporters and related carrier pro- 
teins like BGTl constitute a novel family of integral 
membrane proteins. Their number is likely to increase 
rapidly within the next few years due to the cloning of 
other homologous transporters and transporter 
isoforms. Heterologous expression and sitedirected 
mutagenesis of these proteins will unravel functional 
domains and sites important for transport activity and 
drug action, Moreover, analysis of transporter gene ex- 
pression and regulation might shed light on processes 
underlying brain plasticity. 
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